Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications.
Although trees comprise a primary component of terrestrial species richness, the drivers and temporal scale of divergence in trees remain poorly understood. We examined the landscape-dominant tree,… (More)
Intraspecific hybrid zones involving long-lived woody species are rare and can provide insights into the genetic basis of early-diverging traits in speciation. Within the landscape-dominant Hawaiian… (More)
BackgroundDNA barcoding of land plants has relied traditionally on a small number of markers from the plastid genome. In contrast, low-copy nuclear genes have received little attention as DNA… (More)
Resolving species relationships within recent radiations requires analysis at the interface of phylogenetics and population genetics, where coalescence and hybridization may confound our… (More)
UNLABELLED PREMISE OF THE STUDY Primers were developed to amplify low-copy nuclear genes in Hawaiian Metrosideros (Myrtaceae). • METHODS AND RESULTS Data from a pooled 454 Titanium run of the… (More)
UNLABELLED PREMISE OF THE STUDY Primers were developed to amplify 12 intron-less, low-copy nuclear genes in the Hawaiian genus Clermontia (Campanulaceae), a suspected tetraploid. • METHODS AND… (More)
e16561Background: In the phase 3, open-label, randomized CheckMate 214 trial, nivolumab (N) combined with ipilimumab (I) (N 3 mg/kg + I 1 mg/kg every 3 weeks for 4 doses followed by N 3 mg/kg every...
Abstract The genus Metrosideros (Myrtaceae) comprises 50–60 species found largely across the Pacific Islands. The relationships within this genus, including the circumscriptions of the subgenera… (More)
4517Background: Previous clinical trials of patients (pts) with aRCC, including CheckMate 214, have mostly excluded pts with brain metastases. However, antitumor activity in pts with brain metastas...
564Background: TFS characterizes the antitumor activity of immuno-oncology agents after treatment discontinuation. In CheckMate 214, pts with IMDC intermediate/poor-risk aRCC who discontinued first...